Gapping up
In reaction to earnings/guidance:
- KMI +3.1%, BANC +2.9%, PLXS +2.6%, TRV +2.1%, KEY +2%, WNS +1.7%, WTFC +1.4%, HWC +1.3%, TFC +0.9%, WBS +0.9%, FBC +0.8%, UMPQ +0.7%, BKU +0.6%, SASR +0.5%, BKR +0.5%
Other news:
- GENE +82.8% (provides update on further development on the COVID-19 serious disease risk Polygenic Risk Score Test)
- OCX +11.7% (announces registered direct offering of $25 mln)
- OSUR +10.9% (Oragene Dx saliva collection kit included in industry's first FDA authorization for a whole exome sequencing platform)
- EXPC +10.5% (Cathie Wood's ARK Autonomous Technology & Robotics ETF discloses purchase of 195.4K shares)
- LCTX +9% (CFO resigns)
- BLD +4.4% (acquires LCR Contractors)
- GLPG +4.2% (receives NICE recommendation for Jyseleca for rheumatoid arthritis)
- APT +3.8% (President Biden signs mask mandate on federal property, as expected)
- CMRX +1.9% (prices offering of 11.765 mln shares of common stock at $8.50 per share)
- FBC +0.8% (increases dividend)
- BSX +0.7% (announces agreement to acquire Preventice Solutions)
Analyst comments:
- TELL +10.8% (upgraded to Outperform from Peer Perform at Wolfe Research)
- DBD +7.3% (upgraded to Overweight from Neutral at JP Morgan)
- FSLY +3.9% (upgraded to Outperform from Perform at Oppenheimer)
- CIEN +3.7% (upgraded to Buy from Neutral at BofA Securities)
- UAA +3.2% (upgraded to Buy from Hold at Deutsche Bank)
- SYNA +3% (upgraded to Neutral from Underweight at JP Morgan)
- CPRI +2.1% (upgraded to Buy from Hold at Deutsche Bank)
- FRPT +1.8% (upgraded to Outperform from Perform at Oppenheimer)
- VFC +1.6% (upgraded to Buy from Hold at Deutsche Bank)
- PYPL +1.2% (upgraded to Buy from Neutral at BTIG Research)
- SPR +1.2% (upgraded to Outperform from Neutral at Credit Suisse)